A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
Typically, the only ketamine-derived treatment for depression that insurance will cover is the FDA-approved nasal spray esketamine (Spravato). Because the FDA hasn't approved IV ketamine for ...
Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”.
Research also suggests that esketamine nasal spray doesn’t affect thinking skills the way high doses of ketamine do. What’s Next Along with treatment-resistant depression, Spravato is approved ...
“It’s so life-changing,” said Eldredge. Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market ...
We can help. Stella Mental Health in Encinitas specializes in Spravato (esketamine) nasal spray, ketamine infusion therapy, stellate ganglion blocks (SGB) and integration therapy. Schedule an ...
Medicare does not typically cover ketamine infusions for mental health conditions. However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression.
Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ketamine. It was approved in 2019 for use in adults with major depressive disorder who did not respond ...